Posts tagged PTG-200
Leerink starts Protagonist Therapeutics at outperform

Leerink Partners launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an “outperform” rating and $17 price target in 12 months. The stock closed at $12.08 on Friday.

Protagonist is aiming to become the standard of care therapy for moderate-to- severe irritable bowel disease (IBD) patients, a large and growing market opportunity.

Read More